Business Wire

Transphorm Releases Quality and Reliability Data Behind Recently Announced Device Shipment Numbers

Share

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V gallium nitride (GaN) semiconductors—today announced the industry’s first complete validation data set for GaN power FETs in the 600 V and higher range. This information expands on Transphorm’s December 2018 announcement indicating that the company has shipped over 250,000 GaN FETs to date. What follows provides details behind public Transphorm customer statements citing reliability as a major influencer behind their GaN device selection.

“In the power conversion market—quality, reliability, and performance are the three main factors used when vetting transistors. We’ve always operated with the mindset that prioritizing quality and reliability will result in high voltage GaN’s success,” explained Philip Zuk, Vice President of Technical Marketing Worldwide, Transphorm. “We’re proud to see that strategy deliver positive results and felt it important to release the validation data so that potential and existing customers can understand GaN’s true capabilities.”

Availability of the two new data types, Early Life Failure (ELF) and Field Failure, that round out the validation data set marks another major milestone for high voltage GaN technology. They further position Transphorm’s GaN reliability as competitive to and poised to likely surpass that of alternative solutions—Silicon and Silicon Carbide (SiC)—given that Transphorm’s power conversion technology is in its first maturation stage whereas Silicon transistors have long-since matured and SiC is a decade into its development.

High Voltage GaN Reliability: A Complete View
Transphorm’s complete data set includes five components of product reliability:

  1. Product Qualification: defined by JEDEC and AEC-Q101 Standards.
  2. Testing beyond standard requirements: includes high voltage switching, single event burnout (SEB), HTOL, and HTGB testing at elevated temperatures and voltages.
  3. Intrinsic Lifetime: measures device’s “wear-out” lifetime; also defines failure modes and acceleration factors.
  4. Extrinsic Lifetime or ELF: forecasts Field Failure rates in Failure in Time (FIT) or Parts per Million (ppm) per year rates; used for warranty calculations.
  5. Field Failure: measures device’s actual field performance in customer applications.

“Intrinsic data alone is not enough,” said Ron Barr, Vice President of Quality and Reliability, Transphorm. “Intrinsic testing gives us the acceleration factors that we use in conjunction with Early Life Failure testing to determine the product’s Infant Mortality rate. This makes it easy for customers to accurately vet GaN devices. Pairing intrinsic data with extrinsic data and Field Failure rates provides a complete baseline for how GaN FETs will perform.”

Extrinsic Early Lifetime Failure

Intrinsic failure rates give unrealistically optimistic views of product reliability. Also called Infant Mortality, ELF provides the most realistic view via FIT and ppm rates. Early Lifetime Failure assesses potential defects in materials, design, and process control that may cause parts to fail. Notably, ELF causes most customer warranty claims and typically occurs sooner and at higher rates than wear-out failures. Given this, customers use ELF data to determine warranty risks and costs.

Transphorm’s ELF:

  • FIT: 0.45
  • ppm: 4

Field Failure

Field Failure measures the number of devices that fail in customer systems in production in relation to the total number of parts sold. Transphorm has shipped over 250,000 FETs and accumulated over 1.3 billion field hours of operation resulting in the following Field Failure rates:

  • FIT: 3.1
  • ppm: 27.4 (conservative estimate)

Transphorm’s Field Failures align with that of SiC, which is reported to be less than 5 FIT. Further, Transphorm’s ppm rate continues to decrease over time regardless of application, suggesting that reliability is better than currently reported.

Read High Voltage GaN Switch Reliability for details on Transphorm’s ELF and Field Failure testing.

Intrinsic Lifetime

Intrinsic Lifetime is essentially a device’s theoretical lifetime assuming that material wear-out is the only contributor to the part’s longevity. The data is created using the “Physics of Failure” methodology, which involves measuring time to failure when stressing parts with voltage and temperature, and building related models used to predict ultimate lifetime.

Transphorm’s Intrinsic GaN wear-out:

  • Mean Time Before Failure [MTBF]1: 1e11 hours [11M+ years]
  • Lifetime2 [100 ppm]: 100M hours [11,415 years]

About Transphorm

Transphorm designs, manufactures, and sells the highest performance, highest reliability GaN semiconductors for high-voltage power conversion applications. The company holds one of the largest Power GaN IP portfolios (1000+ issued and pending patents worldwide) and produces the industry’s only JEDEC and AEC-Q101 qualified GaN FETs. Website: www.transphormusa.com China Website: www.transphormchina.com

1 MTBF is the time when 63.2% of the population has failed
2 Lifetime is defined as the wear-out phase of the devices where 100 ppm/year is used

Contact information

Heather Ailara
211 Communications
heather@211comms.com
P: +1.973.567.6040

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 20:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses

Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 15:30:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 13:30:00 CESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt